gallbladder disease and semaglutide Ozempic (Semaglutide): GLP-1 receptor agonist used for type 2 diabetes. It commonly causes dose-related gastrointestinal side-effects, while important serious warnings include pancreatitis, disease, dehydration-related acute kidney injury Understanding the Link Between Weight

JAMA 2014

Blood pressure improvements often accompany semaglutide use, with many patients seeing systolic readings drop by 5-10 mmHg within three months

This is where most people get confused

While there are studies on Ozempic and GLP-1 in mouse models, and they show potential metabolic and reproductive benefits- Ozempic has not been studied in infertile women as a fertility treatment

Weight loss injections, including glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Zepbound), have become increasingly popular for chronic weight management